One Year After Trump's Medicaid Drug Price Pledge, Details Remain Unclear, NPR Reports

A year after President Trump pledged to lower prescription drug prices for Medicaid recipients, key details of how that promise would be carried out remain unresolved, according to a report published by NPR.

The pledge was part of a broader push by the Trump administration to reduce drug costs, which has included agreements with pharmaceutical manufacturers such as Pfizer under a "most favored nation" pricing approach intended to align U.S. prices more closely with those paid in other countries, NPR reported.

However, NPR found that it is still unclear exactly which drugs would be subject to the promised Medicaid price reductions a year after the pledge was made.

Complicating implementation further, NPR reported that any changes to Medicaid drug pricing would require individual states to opt in, meaning the effects of the policy could vary significantly depending on which states choose to participate.

NPR did not report a timeline for when additional details about the affected drugs or state participation might be finalized.